 
        
        
         
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | MEK ↓ ↑ | MEK1 ↓ ↑ | MEK1/2 ↓ ↑ | MEK2 ↓ ↑ | MEK5 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Honokiol | ✔ | 98% | |||||||||||||||||
| Mirdametinib | ++++ MEK, IC50: 0.33 nM | 99%+ | |||||||||||||||||
| Binimetinib | +++ MEK, IC50: 12 nM | 99%+ | |||||||||||||||||
| BI-847325 | ++ MEK1, IC50: 25 nM | +++ MEK2, IC50: 4 nM | 99%+ | ||||||||||||||||
| U0126-EtOH | + MEK1, IC50: 0.07 μM | ++ MEK2, IC50: 0.06 μM | 98% | ||||||||||||||||
| GDC-0623 | ++++ MEK1, IC50: 0.13 nM | 99%+ | |||||||||||||||||
| TAK-733 | ++++ MEK1, IC50: 3.2 nM | 99%+ | |||||||||||||||||
| Trametinib | ++++ MEK1, IC50: 0.92 nM | ++++ MEK2, IC50: 1.8 nM | 99%+ | ||||||||||||||||
| Selumetinib | +++ MEK1, IC50: 14 nM MEK1, Kd: 99 nM | + MEK2, Kd: 530 nM | 99%+ | ||||||||||||||||
| CI-1040 | ++ MEK1, IC50: 17 nM | ++ MEK2, IC50: 17 nM | 99%+ | ||||||||||||||||
| Myricetin | ✔ | 98% | |||||||||||||||||
| Refametinib | ++ MEK1, IC50: 19 nM | ++ MEK2, IC50: 47 nM | 99%+ | ||||||||||||||||
| Cobimetinib | +++ MEK1, IC50: 4.2 nM | 99%+ | |||||||||||||||||
| PD98059 | + MEK1, IC50: 2 μM | 99%+ | |||||||||||||||||
| SL327 | + MEK1, IC50: 0.18 μM | + MEK2, IC50: 0.22 μM | AP-1 | 98+% | |||||||||||||||
| PD318088 | ✔ | 99% | |||||||||||||||||
| AZD8330 | +++ MEK1/2, IC50: 7 nM | 99%+ | |||||||||||||||||
| Pimasertib | 98% | ||||||||||||||||||
| (E/Z)-BIX02189 | ++++ MEK5, IC50: 1.5 nM | 99%+ | |||||||||||||||||
| (E/Z)-BIX02188 | +++ MEK5, IC50: 4.3 nM | 99% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 | 
 | 
| 描述 | MEKs, which are members of the MAPKK family, can activate both ERK1 and ERK2 by catalyzing the phosphorylation on T202/Y204. Also MEK itself can be phosphorylated and activated through Ras when the upstream signaling is activated by extracellular stimuli, including growth factors, hormones etc.. U0126 is a selective MEK1/2 inhibitor with IC50 value of 70/60nM, but not ERK or Raf[1][2]. Co-treatment with U0126 for 15min at concentration ranging in 1nM-10μM caused inhibition of PMA-induced p-ERK, the target of MEK1/2 in a dose-dependent manner in COS-7 cells. An in vitro study showed that U0126 represented much more potency to both wild type and ΔN3-S218E/S222D MEK compared with the another MEK1/2 inhibitor, PD98059[2]. An in vivo study showed that U0126 is brain-permeable. Intravenous injection with U0126 at dose of 100mg/kg could reduce p-ERK1/2 in hippocampus after 10 min of reperfusion after 3.5 min bilateral carotid artery occlusion in male gerbils. Intravenous administration of U0126 at dose of 100-200mg/kg showed protective effect on the hippocampus against forebrain ischemia in male gerbils. Moreover, treatment with U0126 at 3 hours post ischemia significantly reduced volume after transient focal cerebral ischemia, accompanied with reduced p-ERK in the damaged brain areas[3]. Also, it has been reported that U0126 helped maintain human pluripotent stem cells[4]. | 
| 作用机制 | U0126 is a non-competitive inhibitor of MEK1/2, which can bind a common or two overlapping sites on MEK.[2] | 
| Concentration | Treated Time | Description | References | |
| MEL10 cells | 10 µM | 5 days | U0126 induced cyclin D1-negative senescence. | Cell Death Differ. 2013 Sep;20(9):1241-9. | 
| TE671 cells | 40 μM | 7 days | U0126 significantly reduced the number of CD133 and CXCR4 positive cells in TE671 cells and inhibited rhabdosphere formation. | Mol Cancer. 2016 Feb 20;15:16. | 
| RD cells | 10 μM | 15 days | Inhibition of the MEK/ERK pathway in RD cells significantly reduced rhabdosphere formation and downregulated the expression of stem cell markers CD133, CXCR4, and Nanog, while enhancing ALDH, MAPK p38, and differentiative myogenic markers. | Mol Cancer. 2016 Feb 20;15:16. | 
| Canine tracheal smooth muscle cells | 15 μM or 30 μM | ≥45 min | U0126 increased the force-fluctuation-induced relengthening (FFIR) of acetylcholine-contracted canine tracheal smooth muscle strips in a concentration-dependent manner, and this effect was negatively correlated with the phosphorylation of high-molecular-weight caldesmon (h-caldesmon). | Eur Respir J. 2010 Sep;36(3):630-7. | 
| HT-p16 cells | 10 µM | 24 h | U0126 completely eliminated cyclin D1 accumulation, making it undetectable. | Cell Death Differ. 2013 Sep;20(9):1241-9. | 
| HT-p21 cells | 10 µM | 24 h | U0126 completely eliminated cyclin D1 accumulation, making it undetectable. | Cell Death Differ. 2013 Sep;20(9):1241-9. | 
| mouse primary cultured cortical neurons | 10 µM | U0126 dramatically inhibited neuronal cell death by exposure to SNP, with a maximum inhibition at 10 µM. | Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11569-74. | |
| mouse primary cultured cortical neurons | 10 µM | 24 h | U0126 inhibited neuronal cell death, protecting cortical neurons against oxygen deprivation. | Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11569-74. | 
| Administration | Dosage | Frequency | Description | References | ||
| NOD/SCID mice | Embryonal rhabdomyosarcoma model | Intraperitoneal injection | 25 μM/kg | 3 times per week for 4 weeks | Intraperitoneal administration of U0126 significantly inhibited tumor growth induced by rhabdosphere cells, delayed tumor progression time, and reduced tumor volume. | Mol Cancer. 2016 Feb 20;15:16. | 
| Gerbils | Forebrain ischemia model | I.v. administration | 100 mg/kg | Single injection, 10 min before ischemia | U0126 reduced the loss of CA1 pyramidal cells at 7 days, protecting the hippocampus against forebrain ischemia. | Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11569-74. | 
| Dose | Mice: 30 mg/kg[7] (p.o.) Rat: 30 mg/kg[8] (i.p.), 30 mg/kg[9] (s.c.) | 
| Administration | p.o., i.p., s.c. | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.63mL 0.53mL 0.26mL | 13.14mL 2.63mL 1.31mL | 26.28mL 5.26mL 2.63mL | |
| CAS号 | 1173097-76-1 | 
| 分子式 | C20H22N6OS2 | 
| 分子量 | 426.56 | 
| SMILES Code | N#CC(/C(C#N)=C(N)/SC1=CC=CC=C1N)=C(N)\SC2=CC=CC=C2N.CCO | 
| MDL No. | MFCD22628895 | 
| 别名 | |
| 运输 | 蓝冰 | 
| InChI Key | CFQULUVMLGZVAF-OYJDLGDISA-N | 
| Pubchem ID | 16220066 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, 2-8°C | 
| 溶解方案 | DMSO: 50 mg/mL(117.22 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 无水乙醇: 2 mg/mL(4.69 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1